Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 79 references it cites were found in a registry or an index; 17 of the 68 sources its claims cite were checked for support.
Abstract
The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS mutation status and subtypes were prognostic ( p < 0.001). Relative to patients with KRAS wildtype tumors (median OS 38 months), patients with KRAS G12R had a similar OS (median 34 months), while patients with KRAS Q61 and KRAS G12D mutated tumors had shorter OS (median 20 months [HR: 1.9, 95% CI 1.2–3.0, p = 0.006] and 22 months [HR: 1.7, 95% CI 1.3–2.3, p < 0.001], respectively). There was enrichment of KRAS G12D mutation in metastatic tumors (34% vs 24%, OR: 1.7, 95% CI 1.2–2.4, p = 0.001) and enrichment of KRAS G12R in well and moderately differentiated tumors (14% vs 9%, OR: 1.7, 95% CI 1.05–2.99, p = 0.04). Similar findings were observed in the external validation cohort (PanCAN’s Know Your Tumor® dataset, n = 408).
Overview
CoChat Summary
TL;DR
In a retrospective MD Anderson cohort of 803 patients with pancreatic ductal adenocarcinoma and an external PanCAN Know Your Tumor validation cohort (n = 408), KRAS mutation status and allele subtypes were prognostic for overall survival, with KRASG12R and KRAS wildtype tumors surviving longer than KRASG12D or KRASQ61 tumors. Co-mutations, including ARID1A and SMAD4, and KRAS/TP53/CDKN2A molecular subtypes were also associated with overall survival.
Key findings
- KRAS mutation status and subtype were prognostic of OS (p < 0.001). Among 703 patients tested for KRAS, 578 (82%) were KRAS-mutant; among KRAS-mutant tumors, KRASG12D was 39%, KRASG12V 31%, KRASG12R 14%, KRASQ61 6%, and other uncommon variants 9%. Median OS was 38 months for KRAS wildtype, 34 months for KRASG12R (HR: 1, 95% CI 0.71–1.5, p = 0.88), 20 months for KRASQ61 (HR: 1.9, 95% CI 1.2–3.0, p = 0.006), and 22 months for KRASG12D (HR: 1.7, 95% CI 1.3–2.3, p < 0.001).
- KRASG12D was enriched in metastatic stage IV versus localized disease (34% vs 24%, OR: 1.7, 95% CI 1.2–2.4, p = 0.001), and KRASG12R was enriched in well/moderately differentiated versus poorly differentiated/anaplastic tumors (14% vs 9%, OR: 1.7, 95% CI 1.05–2.99, p = 0.04).
- TP53 was the most frequent KRAS co-mutation (67%), followed by CDKN2A (17%), SMAD4 (11%), and ARID1A (6%). ARID1A mutation was associated with worse OS (median 18 vs 31 months; HR: 1.6, 95% CI 0.99–2.6, p = 0.05), while SMAD4 mutation was associated with better OS (median 35 vs 27 months; HR: 0.67, 95% CI 0.46–0.99, p = 0.046). In metastatic patients with known KRAS, TP53, and CDKN2A status (n = 232), triple-negative tumors had the longest median OS (28 months) and CDKN2A-predominant tumors the worst (12 months; p = 0.014).
- In the PanCAN KYT validation cohort, KRASG12R was associated with longer median OS (32 months) than KRASQ61 (16 months; HR: 2.6, 95% CI 0.88–7.8, p = 0.02) and KRASG12D (23 months; HR: 1.68, 95% CI 1.06–2.65, p = 0.04).
Methods
- Retrospective study of 803 patients with PDAC who had tumor tissue somatic mutation testing at MD Anderson Cancer Center (42% with metastatic disease at diagnosis; median age 63 years; 43% female; median follow-up 41 months; median OS 19 months). External validation used PanCAN’s Know Your Tumor dataset (n = 408).
- Clinical, histopathologic, and molecular data were extracted from the EHR and tumor registry using Palantir Foundry; molecular testing was performed in a CAP-accredited/CLIA-certified laboratory, with gene panels evolving over time. Co-mutation analysis included patients tested with multigene panels (n = 513). KYT samples were sequenced with the Tempus xT NGS panel covering 648 genes.
- OS was calculated from initial diagnosis to death or last contact; Kaplan–Meier curves and log-rank tests were used, and univariate Cox proportional hazards models estimated HRs. Co-occurrence/mutual exclusivity was assessed with Fisher’s exact test and Benjamini–Hochberg FDR correction (FDR-corrected p < 0.1 significant); two-sided p < 0.05 was considered significant.
Limitations
- Stated by the paper: heterogeneities in patient populations and tumor mutation testing methods/gene panels; only patients with tissue molecular testing at MD Anderson were included, and patients tested on other panels were excluded; retrospective single tertiary-institution design with ascertainment bias; external validation cohort had limited clinical information and no treatment history; tumor genomic factors may not be the main contributor to allele-specific outcomes; correlative tissue and blood samples were unavailable to evaluate non-genomic factors.
- Evident from the text: substantial missing data limit interpretation, including stage not available for 59.8%, histology grade for 68.1%, and race/ethnicity for 52.2% of the KYT cohort, with missing data also present in the MD Anderson cohort (e.g., stage 12.7%, grade 18.6%). Rare subtypes were grouped (KRASQ61 variants together; KRASG12C with other uncommon mutations), which may obscure allele-specific effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
10 Valid · 2 Not valid · 28 Not checked · 74 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study comparing KRASG12C (n = 30) and other KRAS mutations reported longer median OS (starting from the first line therapy, p = 0.03) for KRAS wildtype tumors (n = 91) in patients with metastatic PDAC, which was consistent with our findings of better survival in KRAS wildtype patients12”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Discussion
What the sources say
- Partly supportedcites [12] Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis. Oncol. 6, 91 (2022). sourceExperimental — accuracy not yet measured
The Results 'Clinico-genomic database outcomes analysis' section does report the mPDAC finding the citation is offered for: KRAS G12C tumors had worse OS than KRAS negative tumors (5.9 vs. 8.8 mos, HR 0.59, p = 0.03), i.e. longer median OS for KRAS wildtype, and the Methods ('Statistical considerations'; 'FM-Flatiron CGDB') define rwOS as time from first therapy administration in patients who started 1L after tissue CGP — so the 'starting from the first line therapy' qualifier matches. However, the subgroup sizes attributed (n = 30 for KRAS G12C, n = 91 for KRAS wildtype) are nowhere in our copy (it gives only the 1398 eligible mPDAC patients and refers subgroup counts to Supplemental Table 17/Fig. 5c). The citing sentence also states the OS difference as a plain finding, whereas the source calls it 'statistically worse, though clinically similar' and 'marginally inferior', noting it was not significant in the multivariable model (Fig. 5c). (LLM, conf=0.75)
plainstates an associationn = 91- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A therapeutic approach targeting CDKN2A in KRAS-mutated PDAC is under investigation; however, clinical activity of CDK4/6 inhibitors was not seen in early-phase trials55,56.”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Discussion
What the sources say
- Supportedcites [55] Goodwin, C. M. et al. Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 83, 141–157 (2023). source
The Introduction (p. 1) of our copy states that 'the outcomes of clinical evaluation of CDK4/6 inhibitors in PDAC has been disappointing,' citing a phase I evaluation of ribociclib plus everolimus (NCT02985125) that 'resulted in no significant clinical response' and a phase II abemaciclib trial (NCT02981342) with no significant overall-survival improvement. The Abstract likewise states CDK4/6 inhibition 'has shown limited clinical efficacy in PDAC,' and the Results section refers to 'the lack of clinical efficacy seen with single agent CDK4/6 inhibitor treatment in PDAC.' This matches the attributed claim of absent clinical activity in early-phase trials. (LLM, conf=0.90)
- Not checked yetcites [56] Baghdadi, T. A. et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis. Oncol. 3, 1–8 (2019). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with resected PDAC and somatic CDKN2A loss had worse survival (median DFS 11.5 and OS 19.7) compared to patients with wildtype CDKN2A (median DFS 14.8 and median OS 24.6)39.”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Discussion
What the sources say
- Partly supportedcites [39] Qian et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 4, e173420–e173420 (2018). sourceExperimental — accuracy not yet measured
The Abstract (Results) states median OS of 19.7 versus 24.6 months for patients whose tumors lacked vs retained CDKN2A in 356 patients with resected pancreatic adenocarcinoma, and the RESULTS confirm worse DFS and OS with CDKN2A loss (referring to Table 1) — so the OS figures and the direction of effect match. However, the specific median DFS values of 11.5 and 14.8 months do not appear anywhere in our copy (searched: 'median disease-free survival 11.5 14.8', 'CDKN2A median DFS table'); they reside only in Table 1, which our copy references but does not reproduce. Additionally, the claim frames the contrast as 'somatic CDKN2A loss' vs 'wildtype CDKN2A', whereas the METHODS state CDKN2A was classified as intact or lost by IHC protein expression, with the authors noting NGS cannot detect methylation-mediated silencing — so the genotype wording is not what this source measured. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When limited to patients with stage IV metastatic disease (n = 302), KRAS mutation remained significantly associated with OS (p = 0.034) (Fig. 2b).”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Results > KRAS mutation status and allele subtype association with OS
plainstates an associationn = 302- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and GNAS (OR: 0.05, FDR-corrected p = 6.65E-05) mutations.”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Results > KRAS Co-mutations and OS
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims
Create a free account to see all 114 claims and to verify the 51 references still open.
- Probably not a substantial claim. 41
- It may state two separate claims as one. 30
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Over 20% of KRAS-mutant NSCLC and PDAC cases have been found to have inactivating CDKN2A co-mutations [122, 123].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [123]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Results > KRAS Co-mutations and OS
“TP53 (69%, N = 418 of 608)”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Results > Patient characteristics
“TP53 was tested in 604 patients, 418 (69%) of whom were positive”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Results > KRAS Co-mutations and OS
“SMARCA4 (OR: 5.17, 95% CI 1.15–8.44, FDR-corrected p = 0.1)”
§ Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma > Discussion
“SMARCA4 (OR: 5.17, 95% CI 1.15–18.44, FDR-corrected p = 0.1)”
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“The median OS for the other available fi rst-line chemotherapy regimen, gemcitabine/nab-paclitaxel, is 8.5 months with an ORR of 23% and median PFS of 5.5 months 5 .”
InfluentialMaftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationHaplotype-based variant detection from short-read sequencing
Garrison, E., & Marth, G. (2012) · arXiv · doi:10.48550/arxiv.1207.3907 · Cited by 3,700
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“ARID1A[20] RNF43 [ 19] ATM [ 16] KMT2C [ 16] KMT2D [ 15] RB1 [ 15] GNAS [ 13] KDM6A [ 11] BRCA2 [ 7] FLCN [ 7] APC [ 6] PALB2 [ 6] SMARCA4 [ 6] ARID1B [ 5] BCOR [ 5] LRP1B [ 5] NF1[ 5] PTEN [ 5] U2AF1 [ 5] AMER1 [ 4] In summary, we reported the KRAS mutation allele-speci fi c clinical outcomes in…”
Self-citationMizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Moreover, ef fi cacy of both sotorasib and adagrasib against PDAC has also been observed 14 – 18 .”
Background
Research works printed but not linked: 1
- Govindan, R. et al. Phase 1 study of AMG 510, a novel molecule targeting KRAS G12C mutant solid. Ann. Oncol. 860, v159–v193 (2019).
Cited by
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 131
Varghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 142
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
Laethem, J. V., Borbath, I., Prenen, H., Geboes, K., Lambert, A., Mitry, E., Cassier, P. A., Blanc, J., Pilla, L., Feliú, J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00263-8 · Cited by 67
Metadata
- Authors
- Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., Wolff, R. A., Pant, S., Lee, M. S., Willis, J., Overman, M., Doss, S., Matrisian, L., Hurd, M. W., Snyder, R., Katz, M. H. G., Wang, H., Maitra, A., Shen, J. P., & Zhao, D.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Pancreatic Cancer Action Network (US)
- Corresponding author
- Zhao, Dan
- ORCID
- Yousef, Abdelrahman
- Yousef, Mahmoud
- Chowdhury, Saikat
- Abdilleh, Kawther
- Knafl, Mark
- Edelkamp, Paul
- Alfaro-Munoz, Kristin
- Smaglo, Brandon G.
- Wolff, Robert A.
- Pant, Shubham
- Lee, Michael S.
- Willis, Jason
- Overman, Michael
- Doss, Sudheer
- Matrisian, Lynn
- Hurd, Mark W.
- Snyder, Rebecca
- Katz, Matthew H. G.
- Wang, Huamin
- Maitra, Anirban
- Shen, John Paul
- Zhao, Dan
- Venue
- npj Precision Oncology
- Published
- 2024-02-03
- Volume
- 8
- Issue
- 1
- Pages
- 27-27
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC10838312
- OpenAlex
- W4391514138
- Semantic Scholar
- 915d53dd44f3b22df1a36a3a8bc6c9e8bd6160a7
- Cited by
- 93
- References
- 79
- Citations by year
- 2026: 28 · 2025: 40 · 2024: 25
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RR180035)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- KRAS mutation, pancreatic ductal adenocarcinoma, KRAS G12D, KRAS G12R, prognostic factors, overall survival, metastatic pancreatic cancer, tumor differentiation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1038/s41698-024-00505-0
- The paper
- Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., Wolff, R. A., Pant, S., Lee, M. S., Willis, J., Overman, M., Doss, S., Matrisian, L., Hurd, M. W., Snyder, R., . . . Zhao, D. (2024). Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00505-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.